3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Leukemia, Myeloid, Acute
38
Breast Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
35
Multiple Myeloma
31
Lymphoma, Non-Hodgkin
29
Burkitt Lymphoma
29
Lymphoma
27
Myelodysplastic Syndromes
25
Triple Negative Breast Neoplasms
23
Recurrence
23
Hematologic Neoplasms
22
Lymphoma, B-Cell
21
Lymphoma, Follicular
20
Melanoma
16
Ovarian Neoplasms
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Neoplasm Metastasis
14
Leukemia
14
Hodgkin Disease
13
Neoplasms
12
Leukemia, Biphenotypic, Acute
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Neuroblastoma
11
Leukemia, Myelomonocytic, Chronic
11
Lymphoma, Mantle-Cell
10
Graft vs Host Disease
10
Carcinoma, Non-Small-Cell Lung
10
Lymphoma, T-Cell, Peripheral
9
Interventions
Magnetic Resonance Spectroscopy
6
lutetium Lu 177 dotatate
4
Specimen Handling
4
Proton Therapy
3
Bevacizumab
3
gallium Ga 68 dotatate
2
abemaciclib
2
Protons
2
Observation
2
Ga(III)-DOTATOC
2
Everolimus
2
Elasticity Imaging Techniques
2
trametinib
1
regorafenib
1
pembrolizumab
1
olaparib
1
neratinib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
capivasertib
1
cabozantinib
1
brigatinib
1
auricularum
1
apatinib
1
X-Rays
1
Watchful Waiting
1
Thrombectomy
1
Tablets
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Meningioma
×
Cyclophosphamide
×
Clear all
NCT06640582
2024-11-05
BAH2472
Essen Biotech
Phase 1/2
Recruiting
85 enrolled